Cocrystal Pharma, Inc. (COCP)Healthcare | Biotechnology | Bothell, United States | NasdaqCM
1.51 USD
Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:27 a.m. EDT
COCP presents a high-risk, high-reward short-term opportunity driven by FDA Fast Track momentum for its norovirus treatment, yet carries severe long-term caution flags due to negative earnings, significant cash burn, and a lack of sustainable capital generation. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.105756 |
| AutoETS | 0.110448 |
| MSTL | 0.112559 |
| AutoARIMA | 0.116714 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 14.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.005 |
| Excess Kurtosis | -0.01 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 23.772 |
| Market Cap | 20,816,496 |
| Forward P/E | -2.36 |
| Beta | 1.18 |
| Website | https://www.cocrystalpharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.08633089 |
| Address1 | 19,805 North Creek Parkway |
| All Time High | 1,440.0 |
| All Time Low | 0.86 |
| Ask | 1.53 |
| Ask Size | 6 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 547,370 |
| Average Daily Volume3 Month | 2,454,619 |
| Average Volume | 2,454,619 |
| Average Volume10Days | 547,370 |
| Beta | 1.182 |
| Bid | 1.47 |
| Bid Size | 6 |
| Book Value | 0.459 |
| City | Bothell |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.51 |
| Current Ratio | 3.681 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.53 |
| Day Low | 1.48 |
| Debt To Equity | 23.772 |
| Display Name | Cocrystal Pharma |
| Dividend Date | 1,516,752,000 |
| Earnings Timestamp End | 1,755,084,600 |
| Earnings Timestamp Start | 1,755,084,600 |
| Ebitda | -8,947,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.71 |
| Enterprise Value | 15,296,496 |
| Eps Current Year | -0.67 |
| Eps Forward | -0.64 |
| Eps Trailing Twelve Months | -0.78 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.13 |
| Fifty Day Average Change | 0.38 |
| Fifty Day Average Change Percent | 0.33628318 |
| Fifty Two Week Change Percent | 8.633089 |
| Fifty Two Week High | 2.67 |
| Fifty Two Week High Change | -1.1600001 |
| Fifty Two Week High Change Percent | -0.43445694 |
| Fifty Two Week Low | 0.86 |
| Fifty Two Week Low Change | 0.65 |
| Fifty Two Week Low Change Percent | 0.7558139 |
| Fifty Two Week Range | 0.86 - 2.67 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,329,921,000,000 |
| Float Shares | 9,123,277 |
| Forward Eps | -0.64 |
| Forward P E | -2.359375 |
| Free Cashflow | -4,946,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 10 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -5,055,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.32834 |
| Held Percent Institutions | 0.05566 |
| Implied Shares Outstanding | 13,785,759 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,665,446,400 |
| Last Split Factor | 1:12 |
| Long Business Summary | Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington. |
| Long Name | Cocrystal Pharma, Inc. |
| Market | us_market |
| Market Cap | 20,816,496 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_49062639 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -8,831,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 20,816,496 |
| Number Of Analyst Opinions | 3 |
| Open | 1.51 |
| Operating Cashflow | -8,192,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 877 262 7123 |
| Pre Market Change | -0.01999998 |
| Pre Market Change Percent | -1.3245021 |
| Pre Market Price | 1.49 |
| Pre Market Time | 1,776,777,569 |
| Previous Close | 1.51 |
| Price Eps Current Year | -2.2537313 |
| Price Hint | 4 |
| Price To Book | 3.2897604 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.498 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 1.53 |
| Regular Market Day Low | 1.48 |
| Regular Market Day Range | 1.48 - 1.53 |
| Regular Market Open | 1.51 |
| Regular Market Previous Close | 1.51 |
| Regular Market Price | 1.51 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 178,202 |
| Return On Assets | -0.48661 |
| Return On Equity | -1.11404 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 13,785,759 |
| Shares Percent Shares Out | 0.0108 |
| Shares Short | 148,911 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 263,840 |
| Short Name | Cocrystal Pharma, Inc. |
| Short Percent Of Float | 0.0176 |
| Short Ratio | 3.45 |
| Source Interval | 15 |
| State | WA |
| Symbol | COCP |
| Target High Price | 10.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 8.0 |
| Target Median Price | 8.0 |
| Total Cash | 7,025,000 |
| Total Cash Per Share | 0.51 |
| Total Debt | 1,505,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.78 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.22545 |
| Two Hundred Day Average Change | 0.28454995 |
| Two Hundred Day Average Change Percent | 0.23220037 |
| Type Disp | Equity |
| Volume | 178,202 |
| Website | https://www.cocrystalpharma.com |
| Zip | 98,011 |